Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation
In Vitro Cellular & Developmental Biology - Animal · 2024-10 · 60 (9) · 1085-1098
DOI: 10.1007/s11626-024-00960-w ↗Kurz gefasst
Fachartikel in der Zeitschrift In Vitro Cellular & Developmental Biology - Animal, online erschienen am 09.09.2024. Verfasst von Liqi Peng und 4 weiteren Autor:innen. Beteiligte Einrichtung: First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China. Hauptthemen laut MEDLINE: Ginsenosides, Heart Failure, Apoptosis, Down-Regulation. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 45 Literaturangaben. Gefördert von: the Scientific Research Project of Traditional Chinese Medicine in Hunan Province, the Scientific Research Program of Hunan Provincial Health Commission, the National Innovation and Entrepreneurship Training Program for College Students.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
In this study, we investigated the potential therapeutic mechanism of ginsenoside Rg1 (GRg1) in chronic heart failure (CHF), focusing on its regulation of ERK1/2 protein phosphorylation. H9c2 cardiomyocytes and SD rats were divided into the control group, CHF (ADR) group, and CHF+ginsenoside Rg1 group using an isolated cardiomyocyte model and an in vivo CHF rat model induced by adriamycin (ADR). Cell viability, proliferation, apoptosis, and the expression of relevant proteins were measured to assess the effects of GRg1. The results showed that treatment with GRg1 increased cell activity and proliferation, while significantly reducing levels of inflammatory and apoptotic factors compared to the CHF (ADR) group. Moreover, the CHF+ginsenoside Rg1 group exhibited higher levels of Bcl-2 mRNA and protein expression, as well as lower levels of Caspase3 and Bax mRNA and protein expression, compared to the CHF (ADR) group. Notably, the CHF+ginsenoside Rg1 group displayed decreased serum NT-proBNP levels and heart weight/body weight (HW/BW) index. Furthermore, the electrocardiogram of rats in the CHF+ginsenoside Rg1 group resembled that of rats in the control group. Overall, our findings suggested that GRg1 alleviated CHF by inhibiting ERK1/2 protein phosphorylation, thereby inhibiting apoptosis, enhancing cell activity and proliferation, and reducing cardiac inflammatory responses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- First Clinical College of Traditional Chinese Medicine, Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.
- Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China.
- The First Hospital of Hunan University of Chinese Medicine, Changsha, 410007, Hunan, China.
- Hunan University of Chinese Medicine, Changsha, 410208, Hunan, China. tangyp@hnucm.edu.cn.
Förderung
- the Scientific Research Project of Traditional Chinese Medicine in Hunan Province
- the Scientific Research Program of Hunan Provincial Health Commission
- the National Innovation and Entrepreneurship Training Program for College Students
- the Innovation and Entrepreneurship Training Program for College Students in Hunan Province
Zitieren
APA
Peng, L., Li, S., Cai, H., Chen, X., & Tang, Y. (2024). Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation. In Vitro Cellular & Developmental Biology - Animal, 60(9), 1085-1098. https://doi.org/10.1007/s11626-024-00960-w
Vancouver
Peng L, Li S, Cai H, Chen X, Tang Y. Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation. In Vitro Cellular & Developmental Biology - Animal. 2024;60(9):1085-1098. doi:10.1007/s11626-024-00960-w
BibTeX
@article{Peng2024,
author = {Peng, Liqi and Li, Shaodong and Cai, Huzhi and Chen, Xueliang and Tang, Yanping},
title = {Ginsenoside Rg1 treats chronic heart failure by downregulating ERK1/2 protein phosphorylation},
journal = {In Vitro Cellular & Developmental Biology - Animal},
year = {2024},
volume = {60},
number = {9},
pages = {1085--1098},
doi = {10.1007/s11626-024-00960-w}
}
EUVIMED